146 related articles for article (PubMed ID: 18614274)
1. PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging.
Loeb S; Kettermann A; Ferrucci L; Landis P; Metter EJ; Carter HB
Eur Urol; 2008 Nov; 54(5):1073-80. PubMed ID: 18614274
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
Vickers AJ; Wolters T; Savage CJ; Cronin AM; O'Brien MF; Pettersson K; Roobol MJ; Aus G; Scardino PT; Hugosson J; Schröder FH; Lilja H
Eur Urol; 2009 Nov; 56(5):753-60. PubMed ID: 19682790
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time.
Ng MK; Van As N; Thomas K; Woode-Amissah R; Horwich A; Huddart R; Khoo V; Thompson A; Dearnaley D; Parker C
BJU Int; 2009 Apr; 103(7):872-6. PubMed ID: 18990146
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
O'Brien MF; Cronin AM; Fearn PA; Smith B; Stasi J; Guillonneau B; Scardino PT; Eastham JA; Vickers AJ; Lilja H
J Clin Oncol; 2009 Aug; 27(22):3591-7. PubMed ID: 19506163
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen velocity (PSAV) and PSAV per initial volume (PSAVD) for early detection of prostate cancer in Chinese men.
Zheng XY; Zhang P; Xie LP; You QH; Cai BS; Qin J
Asian Pac J Cancer Prev; 2012; 13(11):5529-33. PubMed ID: 23317212
[TBL] [Abstract][Full Text] [Related]
6. Long-term prostate-specific antigen velocity in improved classification of prostate cancer risk and mortality.
Ørsted DD; Bojesen SE; Kamstrup PR; Nordestgaard BG
Eur Urol; 2013 Sep; 64(3):384-93. PubMed ID: 23398767
[TBL] [Abstract][Full Text] [Related]
7. PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml.
Fang J; Metter EJ; Landis P; Carter HB
Urology; 2002 Jun; 59(6):889-93; discussion 893-4. PubMed ID: 12031375
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.
Loeb S; Metter EJ; Kan D; Roehl KA; Catalona WJ
BJU Int; 2012 Feb; 109(4):508-13; discussion 513-4. PubMed ID: 22296334
[TBL] [Abstract][Full Text] [Related]
9. Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer.
Berger AP; Deibl M; Strasak A; Bektic J; Pelzer AE; Klocker H; Steiner H; Fritsche G; Bartsch G; Horninger W
Urology; 2007 Jan; 69(1):134-8. PubMed ID: 17270635
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability.
Carter HB; Kettermann A; Ferrucci L; Landis P; Metter EJ
Urology; 2007 Oct; 70(4):685-90. PubMed ID: 17991538
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
12. Distribution of PSA velocity by total PSA levels: data from the Baltimore Longitudinal Study of Aging.
Loeb S; Carter HB; Schaeffer EM; Kettermann A; Ferrucci L; Metter EJ
Urology; 2011 Jan; 77(1):143-7. PubMed ID: 21195835
[TBL] [Abstract][Full Text] [Related]
13. The utility of PSA velocity in prediction of prostate cancer and high grade cancer after an initially negative prostate biopsy.
Elshafei A; Li YH; Hatem A; Moussa AS; Ethan V; Krishnan N; Li J; Jones JS
Prostate; 2013 Dec; 73(16):1796-802. PubMed ID: 24038200
[TBL] [Abstract][Full Text] [Related]
14. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.
Carter HB; Ferrucci L; Kettermann A; Landis P; Wright EJ; Epstein JI; Trock BJ; Metter EJ
J Natl Cancer Inst; 2006 Nov; 98(21):1521-7. PubMed ID: 17077354
[TBL] [Abstract][Full Text] [Related]
15. Prostate specific antigen velocity per prostate volume: a novel tool for prostate biopsy prediction.
Choi SY; Chang IH; Kim YS; Kim TH; Kim W; Myung SC
Urology; 2011 Oct; 78(4):874-9. PubMed ID: 21791361
[TBL] [Abstract][Full Text] [Related]
16. Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
Kumar A; Godoy G; Taneja SS
Can J Urol; 2009 Jun; 16(3):4655-9. PubMed ID: 19497172
[TBL] [Abstract][Full Text] [Related]
17. Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy.
Spurgeon SE; Mongoue-Tchokote S; Collins L; Priest R; Hsieh YC; Peters LM; Beer TM; Mori M; Garzotto M
Urology; 2007 May; 69(5):931-5. PubMed ID: 17482937
[TBL] [Abstract][Full Text] [Related]
18. Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer.
Kettermann AE; Ferrucci L; Trock BJ; Metter EJ; Loeb S; Carter HB
BJU Int; 2010 Nov; 106(9):1284-90; discussion 1290-2. PubMed ID: 20477823
[TBL] [Abstract][Full Text] [Related]
19. Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH.
King CR; Freedland SJ; Terris MK; Aronson WJ; Kane CJ; Amling CL; Presti JC
Urology; 2007 Apr; 69(4):732-7. PubMed ID: 17445660
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.
Sun L; Moul JW; Hotaling JM; Rampersaud E; Dahm P; Robertson C; Fitzsimons N; Albala D; Polascik TJ
BJU Int; 2007 Apr; 99(4):753-7. PubMed ID: 17244286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
